RG 6061

Drug Profile

RG 6061

Alternative Names: EZN-2968; RG6061; RO-7070179; SPC-2968

Latest Information Update: 07 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Santaris Pharma
  • Developer Enzon Pharmaceuticals; Roche
  • Class Antineoplastics; Antisense oligoribonucleotides
  • Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Hypoxia-inducible factor-1 alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatocellular carcinoma; Lymphoma; Solid tumours

Most Recent Events

  • 07 Aug 2017 Discontinued - Phase-I for Lymphoma in USA (IV) (Roche pipeline, July 2017)
  • 27 Jul 2017 Discontinued - Phase-I for Hepatocellular carcinoma (Second-line therapy or greater) in USA (IV) (Roche pipeline, July 2017)
  • 27 Jul 2017 Discontinued - Phase-I for Solid tumours in USA (IV) (Roche pipeline, August 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top